findmyKOL
Clinical trialNCT04743661Active, not recruitingPhase 2Interventional

131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma

SponsorPediatric Brain Tumor ConsortiumEnrollment62Recurrent EpendymomaRecurrent Medulloblastoma
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

A Phase 2 study investigating the addition of cRIT 131I-omburtamab to irinotecan, temozolomide, and bevacizumab for patients with recurrent medulloblastoma. A feasibility cohort is included to assess the feasibility of incorporating cRIT 131I-omburtamab for patients with recurrent ependymoma. Direct intraventricular delivery of radiolabeled tumor-specific antibodies may aid in both the detection and treatment of recurrent disease for these highly specific pediatric patients with recurrent tumors.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Children'S Hospital Los Angeles

    Los Angeles, California, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Cincinnati Children'S Hospital Medical Center

    Cincinnati, Ohio, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AntihistamineAntipyreticBevacizumabDexamethasoneIrinotecanLiothyronineOmburtamab I-131SSKITemozolomideAnti-emetics
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
4 Apr 2022
Primary completion
1 Apr 2026
Completion
30 Sept 2027
Last update posted
28 Jul 2026
Registered enrollment
62
Registry id
NCT04743661
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.